Literature DB >> 17187364

The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases.

Di-Peng Ou1, Yi-Ming Tao, Fa-Qing Tang, Lian-Yue Yang.   

Abstract

The hepatitis B virus (HBV) is a major cause of human hepatocellular carcinoma (HCC) which has a very high mortality rate due to high incidence of metastasis. It is unknown whether HBV contributes to HCC metastasis. In this report, we present clinical data obtained from HCC patients indicating that the expression of hepatitis B virus X protein (HBx) in HCC is associated with an increased expression of membrane-type 1 matrix metalloproteinase (MT1-MMP), and matrix metalloproteinase-2(MMP-2), which correlates with a poor prognosis. We further demonstrate experimentally that HBx upregulates MT1-MMP, which in turn induces MMP-2. Significantly, HBx-mediated MMP activation is associated with a marked increase of cell migration, as revealed by both wound-healing and transwell migration assays, suggesting that HBx may facilitate tumor cell invasion by upregulation of MMPs and subsequent destruction of the extracellular matrix. Together, our results support a model in which HBx contributes to HCC metastasis by upregulation of MMPs. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187364     DOI: 10.1002/ijc.22452

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

Review 1.  Potential mechanisms of hepatitis B virus induced liver injury.

Authors:  Mohd Suhail; Hany Abdel-Hafiz; Ashraf Ali; Kaneez Fatima; Ghazi A Damanhouri; Esam Azhar; Adeel Ga Chaudhary; Ishtiaq Qadri
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Caffeoyl pyrrolidine derivative LY52 inhibits hepatocellular carcinoma invasion via suppressing matrix metalloproteinase-2.

Authors:  Xin Zhao; Huanli Xu; Yoshinori Inagaki; Norihiro Kokudo; Wenfang Xu; Jiahong Dong; Wei Tang
Journal:  Hepatol Int       Date:  2010-12-21       Impact factor: 6.047

3.  A mutant of hepatitis B virus X protein (HBx Delta 127) enhances hepatoma cell migration via osteopontin involving 5-lipoxygenase.

Authors:  Xuan Zhang; Li-hong Ye; Xiao-dong Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-04-05       Impact factor: 6.150

4.  Hepatitis B virus X protein promotes hepatocellular carcinoma invasion and metastasis via upregulating thioredoxin interacting protein.

Authors:  Zhiliang He; Youjia Yu; Yunhong Nong; Lingyao Du; Cong Liu; Yong Cao; Lang Bai; Hong Tang
Journal:  Oncol Lett       Date:  2017-06-01       Impact factor: 2.967

Review 5.  Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection.

Authors:  Yang Ke; Lin Wang; Le-Qun Li; Jian-Hong Zhong
Journal:  World J Hepatol       Date:  2014-09-27

Review 6.  MICA SNPs and the NKG2D system in virus-induced HCC.

Authors:  Kaku Goto; Naoya Kato
Journal:  J Gastroenterol       Date:  2014-10-01       Impact factor: 7.527

7.  Hepatic stellate cells secretes type I collagen to trigger epithelial mesenchymal transition of hepatoma cells.

Authors:  Ming-Chen Yang; Chih-Jung Wang; Pao-Chi Liao; Chia-Jui Yen; Yan-Shen Shan
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

8.  Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.

Authors:  Lian Yang; Jun He; Libo Chen; Guobin Wang
Journal:  Med Oncol       Date:  2008-12-13       Impact factor: 3.064

Review 9.  Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease.

Authors:  Mark A Feitelson; Helena M G P V Reis; N Lale Tufan; Bill Sun; Jingbo Pan; Zhaorui Lian
Journal:  Cancer Lett       Date:  2009-02-06       Impact factor: 8.679

Review 10.  MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: current status and future prospects.

Authors:  Yi Lin Jane Tan; Wei Ning Chen
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.